Biosimilars - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the biosimilars market size is expected to increase from USD 41.97 billion in 2025 to USD 49.49 billion in 2026 and reach USD 112.93 billion by 2031, growing at a CAGR of 17.95% over 2026-2031.

This report Segments the Industry Into by Product Class (Monoclonal Antibodies, Recombinant Hormones, and More), Indication (Blood Disorders, Autoimmune & Chronic Inflammatory, and More), End User (Hospitals, and More), Manufacturing Type (In-House, and More), Route of Administration (Intravenous, and Sub-Cutaneous), and Geography (North America, Europe, Asia-Pacific, Middle East, and South America).

Global Biosimilars Market Trends and Insights

Imminent Patent Expiry of Multiple Blockbuster Biologics

Market size expansion is being propelled by an unprecedented wave of patent expirations that will unlock an estimated USD 400 billion in reference product sales between 2029 and 2034. Because 25 high-value biologics lose exclusivity in 2025 alone, developers are rushing to secure development slots and manufacturing slots simultaneously. The inference drawn here is that development pipelines are now so crowded that analytical testing capacity, not funding, is emerging as the gating factor for some programs. Companies such as Sandoz have already disclosed pipelines of 28 molecules, demonstrating the scale of the opportunity . Oncology-focused monoclonal antibodies are most exposed, implying lower average selling prices for blockbuster cancer drugs within the forecast period. This disruption will lower treatment costs and widen access, but it also raises competitive intensity in therapeutic areas that previously featured only two or three suppliers.

Escalating Prevalence of Chronic and Autoimmune Diseases

Chronic and autoimmune diseases are surging worldwide, and specialty medicines already account for over half of U.S. prescription expenditure. Consequently, biosimilars targeting these conditions represent the fastest-growing indication cohort, clocking a 23% CAGR from 2025-2030. The inference from rising prevalence data is that payer budgets will come under mounting strain even if biosimilars achieve double-digit market share gains, because absolute patient numbers are rising in parallel. Oncology remains the largest revenue pool today, but autoimmune prescriptions are narrowing that gap as diagnosis rates climb. Real-world evidence from programs in Brazil shows cost savings exceeding 50% when stable patients are switched, suggesting that similar outcomes could surface in other emerging markets. Steady patient migration toward long-term maintenance therapies heightens the commercial attractiveness of chronic-disease biosimilars and incentivizes investment in subcutaneous formulations.

Intrinsic Manufacturing and Analytical Complexity

Developing a biosimilar still costs USD 100-300 million and takes as long as seven to eight years because each molecule must undergo more than 40 orthogonal analytical tests. An inference from these numbers is that capital rationing will steer smaller developers toward narrow, high-value niches rather than broad portfolios. Mammalian cell culture, particularly Chinese Hamster Ovary (CHO) lines, remains the production workhorse because of its human-like glycosylation profile. Complexity rises further when developers target antibody-drug conjugates or fusion proteins, both of which are beginning to surface in pipeline disclosures. Analytical challenges, including glycan profiling and charge variant analysis, require expensive instrumentation, pushing many firms to outsource to specialized CDMOs. High failure rates-hovering around 50 % for late-stage biosimilar programs-signal that expertise, rather than capital alone, determines success probabilities.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Clinician and Patient Confidence Driven by Real-World Evidence
2. Rising Capital Investment, Strategic Alliances, and CMO/CDMO Capacity Expansions
3. Ongoing Interchangeability and Substitution Skepticism in Certain Healthcare Systems

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The biosimilar market size for monoclonal antibodies stands at 47.35 % of total revenue in 2025, and while their aggregate CAGR moderates to the mid-teens, absolute sales continue to rise. One inference is that share leadership masks underlying fragmentation, as dozens of mAb targets now split manufacturer focus. Low-molecular-weight heparins are growing at 20.25% CAGR, signaling that anticoagulation may become the next competitive battleground. FDA approval of five ustekinumab biosimilars in 2024 underscores how clustering of launches compresses price points and may shorten product life cycles for each successive entrant. Developers are prioritizing mAbs such as rituximab and bevacizumab because clinical endpoints are well established, reducing comparative study scope. Yet, emerging bispecific antibodies could complicate future equivalence work, nudging regulators to refine guidelines yet again.

The oncology segment accounts for 54.30% biosimilar market share in 2025, commanding the largest slice of reimbursement budgets. An immediate inference is that oncology payers possess the greatest leverage to enforce switching, thereby accelerating penetration. Autoimmune and inflammatory diseases post a 22.10% forecast CAGR, which implies that by 2031 the revenue gap between the two indications could narrow considerably. Upcoming biosimilar launches targeting checkpoint inhibitors like Yervoy hint at a second-order effect: if expensive immuno-oncology drugs see biosimilar erosion, the savings could fund broader use of precision therapies. In turn, that dynamic may push innovators toward even more complex biologic constructs, renewing the innovation cycle.

Geography Analysis

Europe continues to lead with 36.65 % biosimilar market share, reflecting its pioneering 2006 regulatory path and coordinated procurement policies. Many EU member states have instituted gain-sharing schemes, channeling savings back to hospital budgets, which encourages prescriber engagement. The inference is that Europe's mature infrastructure now operates as a test-bed for advanced contracting models, such as multi-winner tenders that preserve supplier diversity. Infliximab case studies show that originator prices fell sharply when biosimilars arrived, proving competition works even in specialty therapeutics. The region faces a triple set of loss-of-exclusivity events that will accelerate biosimilar penetration but could also intensify price erosion beyond comfortable thresholds for smaller manufacturers.

Asia-Pacific is the fastest-growing territory at a projected 23.10 % CAGR, catalyzed by South Korean giants Samsung Bioepis and Celltrion and by China's regulatory reforms. An inference from capacity figures is that Asia is evolving from a contract-manufacturing hub into a design-and-development powerhouse, as evidenced by the localization of clinical trial infrastructure. India leverages its generics heritage to fast-track biosimilar filings, while Australia and Japan are investing in domestic bioproduction for supply-chain resilience. The pandemic accelerated government incentives for biologics self-sufficiency, suggesting that Asia's share of global approvals will rise faster than global demand growth alone would indicate.

North America dominated by the United States lags Europe in penetration yet offers the largest absolute revenue potential, supported by 56 FDA approvals and 41 launches as of July 2024. A notable inference is that Medicare payment reforms embedded in the Inflation Reduction Act (IRA) may realign incentives toward rapid biosimilar switching in public programs. Projected U.S. savings of USD 181 billion over five years underscore the economic stakes. Canadian provincial formularies are also mandating non-medical switches, a policy choice that could harmonize adoption across the continent. Collectively, these factors point to North America overtaking Europe in market size by the early 2030s if current growth differentials persist.

1. Pfizer
2. Sandoz Group
3. Amgen
4. Viatris
5. Samsung Group
6. Celltrion Healthcare
7. Eli Lilly and Company
8. Biocon Ltd
9. Teva Pharmaceutical Industries
10. Stada Arzneimittel
11. Dr Reddy's Laboratories
12. Coherus Biosciences
13. LG Chem (LG Life Sciences)
14. Intas Pharmaceutical
15. Fresenius
16. Alvotech
17. Bio-Thera Solutions
18. Shanghai Henlius Biotech
19. Lupin
20. Hikma Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support